NCT04524442 2025-01-24Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsAdvanced Accelerator ApplicationsPhase 4 Completed42 enrolled 11 charts